HomeInsightsStock Comparison

Eris Lifesciences Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Eris Lifesciences Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 12, 2025

Key Highlights

  • The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1790 as of 12 Jun 15:30.
  • The P/E Ratio of ERIS Lifesciences Ltd changed from 16.9 on March 2020 to 29.2 on March 2024 . This represents a CAGR of 11.56% over 5 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of ERIS Lifesciences Ltd changed from ₹ 5003 crore on March 2020 to ₹ 11442 crore on March 2024 . This represents a CAGR of 17.99% over 5 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of ERIS Lifesciences Ltd for the Mar '25 is ₹ 713.31 crore as compare to the Sep '24 revenue of ₹ 745.72 crore. This represent the decline of -4.35% The revenue of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 125.98 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16%.
  • The ebitda of ERIS Lifesciences Ltd for the Mar '25 is ₹ 260.4 crore as compare to the Sep '24 ebitda of ₹ 269.06 crore. This represent the decline of -3.22% The ebitda of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 31.21 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16%.
  • The net profit of ERIS Lifesciences Ltd changed from ₹ 93.65 crore to ₹ 102.35 crore over 8 quarters. This represents a CAGR of 4.54% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 7.11 crore to ₹ 17.97 crore over 6 quarters. This represents a CAGR of 85.55% .
  • The Dividend Payout of ERIS Lifesciences Ltd changed from 13.76 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About ERIS Lifesciences Ltd

  • Eris Lifesciences Limited was incorporated on January 25, 2007.
  • Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
  • Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
  • The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
  • It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors.

About Senores Pharmaceuticals Ltd

  • Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
  • Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
  • The Regulated Markets business is focused on Regulated Markets of US and Canada.
  • The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

ERIS Lifesciences Ltd News Hub

News

Eris Lifesciences gains after Q4 PAT climbs 32% YoY to Rs 94 cr

Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarte...

Read more

20 May 2025 13:08

News

ERIS Lifesciences to hold board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 19 May 2...

Read more

14 May 2025 16:22

News

Eris Lifesciences allots 33,287 equity shares under ESOP

Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-...

Read more

06 Mar 2025 13:17

News

Eris Lifesciences avails credit facility of Rs 1,000 cr

Eris Lifesciences has availed credit facilities amounting to Rs 1000 crore from Kotak Mahi...

Read more

21 Feb 2025 09:22

News

Board of ERIS Lifesciences recommends Interim Dividend

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held...

Read more

07 Feb 2025 16:36

News

ERIS Lifesciences schedules board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 7 Februa...

Read more

05 Feb 2025 14:58

Senores Pharmaceuticals Ltd News Hub

News

Senores Pharmaceuticals to hold board meeting

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 15...

Read more

10 May 2025 11:12

News

Senores Pharmaceuticals Inc. to acquire USFDA approved ANDA for Tramadol Tablets

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

09 May 2025 09:29

News

Senores Pharmaceuticals gains on acquiring Topiramate tablets from Wockhardt

Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE. The market size of Topiramate t...

Read more

06 May 2025 10:51

News

Senores inks deal to acquire Wockhardt's ANDA for Topiramate

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

05 May 2025 18:55

News

Senores Pharmaceuticals to acquire 14 ANDAs from Dr Reddy's

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

04 Mar 2025 14:23

News

Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy's Labs

According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approve...

Read more

04 Mar 2025 15:35

SWOT Analysis Of ERIS Lifesciences Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for ERIS Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Senores Pharmaceuticals Ltd?

Market cap of ERIS Lifesciences Ltd is 23,444 Cr while Market cap of Senores Pharmaceuticals Ltd is 2,503 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd?

The stock performance of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd?

As of June 12, 2025, the ERIS Lifesciences Ltd stock price is INR ₹1721.5. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹543.55.

How do dividend payouts of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions